Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity. 2014

Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
Centro de Química e Bioquímica (CQB), Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Ed. C8, Campo Grande, 1749-016 Lisboa, Portugal. Electronic address: filomena.martins@fc.ul.pt.

The disturbing emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has been driving the scientific community to urgently search for new and efficient antitubercular drugs. Despite the various drugs currently under evaluation, isoniazid is still the key and most effective component in all multi-therapeutic regimens recommended by the WHO. This paper describes the QSAR-oriented design, synthesis and in vitro antitubercular activity of several potent isoniazid derivatives (isonicotinoyl hydrazones and isonicotinoyl hydrazides) against H37Rv and two resistant Mtb strains. QSAR studies entailed RFs and ASNNs classification models, as well as MLR models. Strict validation procedures were used to guarantee the models' robustness and predictive ability. Lipophilicity was shown not to be relevant to explain the activity of these derivatives, whereas shorter N-N distances and lengthy substituents lead to more active compounds. Compounds 1, 2, 4, 5 and 6, showed measured activities against H37Rv higher than INH (i.e., MIC ≤ 0.28 μM), while compound 9 exhibited a six fold decrease in MIC against the katG (S315T) mutated strain, by comparison with INH (i.e., 6.9 vs. 43.8 μM). All compounds were ineffective against H37RvINH (ΔkatG), a strain with a full deletion of the katG gene, thus corroborating the importance of KatG in the activation of INH-based compounds. The most potent compounds were also shown not to be cytotoxic up to a concentration 500 times higher than MIC.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D002522 Chlorocebus aethiops A species of CERCOPITHECUS containing three subspecies: C. tantalus, C. pygerythrus, and C. sabeus. They are found in the forests and savannah of Africa. The African green monkey is the natural host of SIMIAN IMMUNODEFICIENCY VIRUS and is used in AIDS research. African Green Monkey,Cercopithecus aethiops,Cercopithecus griseoviridis,Cercopithecus griseus,Cercopithecus pygerythrus,Cercopithecus sabeus,Cercopithecus tantalus,Chlorocebus cynosuros,Chlorocebus cynosurus,Chlorocebus pygerythrus,Green Monkey,Grivet Monkey,Lasiopyga weidholzi,Malbrouck,Malbrouck Monkey,Monkey, African Green,Monkey, Green,Monkey, Grivet,Monkey, Vervet,Savanah Monkey,Vervet Monkey,Savannah Monkey,African Green Monkey,Chlorocebus cynosuro,Green Monkey, African,Green Monkeys,Grivet Monkeys,Malbrouck Monkeys,Malbroucks,Monkey, Malbrouck,Monkey, Savanah,Monkey, Savannah,Savannah Monkeys,Vervet Monkeys
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014709 Vero Cells A CELL LINE derived from the kidney of the African green (vervet) monkey, (CHLOROCEBUS AETHIOPS) used primarily in virus replication studies and plaque assays. Cell, Vero,Cells, Vero,Vero Cell

Related Publications

Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
September 2017, Molecules (Basel, Switzerland),
Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
October 2020, Bioorganic & medicinal chemistry letters,
Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
September 2015, Chemical biology & drug design,
Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
February 2019, European journal of medicinal chemistry,
Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
September 2017, European journal of medicinal chemistry,
Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
December 2018, Bioorganic & medicinal chemistry letters,
Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
September 2020, ACS medicinal chemistry letters,
Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
August 2021, European journal of medicinal chemistry,
Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
September 2021, Bioorganic chemistry,
Filomena Martins, and Susana Santos, and Cristina Ventura, and Ruben Elvas-Leitão, and Lídia Santos, and Susana Vitorino, and Marina Reis, and Vanessa Miranda, and Henrique F Correia, and João Aires-de-Sousa, and Vasyl Kovalishyn, and Diogo A R S Latino, and Jorge Ramos, and Miguel Viveiros
December 2009, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!